Bogdana Balas

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

16h-index4.7kcitations35works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(27), Lung Cancer Research Studies(14), Lung Cancer Diagnosis and Treatment(9), Cancer Genomics and Diagnostics(8), Colorectal Cancer Treatments and Studies(6)

Publications35 total

1053 Shaping the future of immunotherapy safety through consensus—standardization of case report forms
Regular and Young Investigator Award Abstracts·2025Open Access
1531P Evaluating autoimmune diseases as exclusion criteria in immuno-oncology trials
Annals of Oncology·2025
445 The relationship between immune-related adverse events (irAEs) and ctDNA status: exploratory analysis from IMvigor010
Regular and Young Investigator Award Abstracts·2023Open Access
An interventional study of the impact of digital patient monitoring (DPM) on health outcomes, healthcare resource utilization, and feasibility of a combination with at-home treatment (tx) for delivery of systemic anticancer tx in clinical practice.
Journal of Clinical Oncology·2023
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA)
BMJ Open·2023· 5 citedOpen Access
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase<i>–</i>positive non‐small cell lung cancer
CPT Pharmacometrics & Systems Pharmacology·2021· 14 citedOpen Access
Optimized Alectinib Dose Regimen for Treatment of Patients With <i>ALK</i>‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence
Clinical Pharmacology & Therapeutics·2021· 3 citedOpen Access
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
Lung Cancer·2019· 30 cited
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
Lung Cancer·2019· 55 citedOpen Access
Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus
International Journal of Molecular Sciences·2019· 6 citedOpen Access
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study
Journal of Thoracic Oncology·2019· 488 citedOpen Access
Issue Information
The Journal of Clinical Pharmacology·2018Open Access
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
The Journal of Clinical Pharmacology·2018· 26 citedOpen Access
Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population.
Journal of Clinical Oncology·2018· 2 cited
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2018· 5 cited
Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.
Journal of Clinical Oncology·2018· 61 cited
Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
Cancer Chemotherapy and Pharmacology·2018· 28 citedOpen Access
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2017· 82 citedOpen Access
Alectinib versus crizotinib in treatment-naive advanced <i>ALK</i>-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
Journal of Clinical Oncology·2017· 25 cited
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine·2017· 2.4k citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Peter N. Morcos(20), Ali Zeaiter(18), Walter Bordogna(15), Alice T. Shaw(14), Shirish M. Gadgeel(13), Sophie Golding(13), Sai‐Hong Ignatius Ou(11), Elena Guerini(9), D. Ross Camidge(8), Jin Seok Ahn(7), Dong‐Wan Kim(7), Leena Gandhi(7), Luigi De Petris(7), Ramaswamy Govindan(7), James Chih‐Hsin Yang(7), Solange Peters(6), Tony Mok(6), Johannes Noé(5), Tarek Mekhail(5), Fabrice Barlési(5)